Salinomycin  ||| S:0 E:12 ||| NNP
induces  ||| S:12 E:20 ||| VBZ
selective  ||| S:20 E:30 ||| JJ
cytotoxicity  ||| S:30 E:43 ||| NN
to  ||| S:43 E:46 ||| TO
MCF-7  ||| S:46 E:52 ||| CD
mammosphere  ||| S:52 E:64 ||| CD
cells  ||| S:64 E:70 ||| NNS
through  ||| S:70 E:78 ||| IN
targeting  ||| S:78 E:88 ||| VBG
the  ||| S:88 E:92 ||| DT
Hedgehog  ||| S:92 E:101 ||| NNP
signaling  ||| S:101 E:111 ||| FW
pathway  ||| S:111 E:119 ||| FW
Breast  ||| S:119 E:126 ||| FW
cancer  ||| S:126 E:133 ||| FW
stem  ||| S:133 E:138 ||| FW
cells  ||| S:138 E:144 ||| FW
( ||| S:144 E:145 ||| -LRB-
BCSCs ||| S:145 E:150 ||| NNP
)  ||| S:150 E:152 ||| -RRB-
are  ||| S:152 E:156 ||| VBP
believed  ||| S:156 E:165 ||| VBN
to  ||| S:165 E:168 ||| TO
be  ||| S:168 E:171 ||| VB
responsible  ||| S:171 E:183 ||| JJ
for  ||| S:183 E:187 ||| IN
tumor  ||| S:187 E:193 ||| NN
chemoresistance ||| S:193 E:208 ||| NN
,  ||| S:208 E:210 ||| ,
recurrence ||| S:210 E:220 ||| NN
,  ||| S:220 E:222 ||| ,
and  ||| S:222 E:226 ||| CC
metastasis  ||| S:226 E:237 ||| JJ
formation ||| S:237 E:246 ||| NN
.  ||| S:246 E:248 ||| .
Salinomycin  ||| S:248 E:260 ||| NNP
( ||| S:260 E:261 ||| -LRB-
SAL ||| S:261 E:264 ||| NNP
) ||| S:264 E:265 ||| -RRB-
,  ||| S:265 E:267 ||| ,
a  ||| S:267 E:269 ||| DT
carboxylic  ||| S:269 E:280 ||| JJ
polyether  ||| S:280 E:290 ||| JJ
ionophore ||| S:290 E:299 ||| NN
,  ||| S:299 E:301 ||| ,
has  ||| S:301 E:305 ||| VBZ
been  ||| S:305 E:310 ||| VBN
reported  ||| S:310 E:319 ||| VBN
to  ||| S:319 E:322 ||| TO
act  ||| S:322 E:326 ||| VB
as  ||| S:326 E:329 ||| IN
a  ||| S:329 E:331 ||| DT
selective  ||| S:331 E:341 ||| JJ
breast  ||| S:341 E:348 ||| NN
CSC  ||| S:348 E:352 ||| NNP
inhibitor ||| S:352 E:361 ||| NN
.  ||| S:361 E:363 ||| .
However ||| S:363 E:370 ||| RB
,  ||| S:370 E:372 ||| ,
the  ||| S:372 E:376 ||| DT
molecular  ||| S:376 E:386 ||| JJ
mechanisms  ||| S:386 E:397 ||| NNS
underlying  ||| S:397 E:408 ||| VBG
SAL-induced  ||| S:408 E:420 ||| JJ
cytotoxicity  ||| S:420 E:433 ||| NN
on  ||| S:433 E:436 ||| IN
BCSCs  ||| S:436 E:442 ||| NNS
remain  ||| S:442 E:449 ||| VBP
unclear ||| S:449 E:456 ||| JJ
.  ||| S:456 E:458 ||| .
The  ||| S:458 E:462 ||| DT
Hedgehog  ||| S:462 E:471 ||| NNP
( ||| S:471 E:472 ||| -LRB-
Hh ||| S:472 E:474 ||| NNP
)  ||| S:474 E:476 ||| -RRB-
signaling  ||| S:476 E:486 ||| VBG
pathway  ||| S:486 E:494 ||| NN
plays  ||| S:494 E:500 ||| VBZ
an  ||| S:500 E:503 ||| DT
important  ||| S:503 E:513 ||| JJ
role  ||| S:513 E:518 ||| NN
in  ||| S:518 E:521 ||| IN
CSC  ||| S:521 E:525 ||| NNP
maintenance  ||| S:525 E:537 ||| NN
and  ||| S:537 E:541 ||| CC
carcinogenesis ||| S:541 E:555 ||| NN
.  ||| S:555 E:557 ||| .
Here ||| S:557 E:561 ||| RB
,  ||| S:561 E:563 ||| ,
we  ||| S:563 E:566 ||| PRP
investigated  ||| S:566 E:579 ||| VBD
whether  ||| S:579 E:587 ||| IN
SAL  ||| S:587 E:591 ||| NNP
induces  ||| S:591 E:599 ||| VBZ
cytotoxicity  ||| S:599 E:612 ||| VBN
on  ||| S:612 E:615 ||| IN
BCSCs  ||| S:615 E:621 ||| JJ
through  ||| S:621 E:629 ||| IN
targeting  ||| S:629 E:639 ||| VBG
Hh  ||| S:639 E:642 ||| JJ
pathway ||| S:642 E:649 ||| NN
.  ||| S:649 E:651 ||| .
In  ||| S:651 E:654 ||| IN
the  ||| S:654 E:658 ||| DT
present  ||| S:658 E:666 ||| JJ
study ||| S:666 E:671 ||| NN
,  ||| S:671 E:673 ||| ,
we  ||| S:673 E:676 ||| PRP
cultured  ||| S:676 E:685 ||| VBP
breast  ||| S:685 E:692 ||| JJ
cancer  ||| S:692 E:699 ||| NN
MCF-7  ||| S:699 E:705 ||| CD
cells  ||| S:705 E:711 ||| NNS
in  ||| S:711 E:714 ||| IN
suspension  ||| S:714 E:725 ||| NN
in  ||| S:725 E:728 ||| IN
serum-free  ||| S:728 E:739 ||| JJ
medium  ||| S:739 E:746 ||| NN
to  ||| S:746 E:749 ||| TO
obtain  ||| S:749 E:756 ||| VB
breast  ||| S:756 E:763 ||| FW
CSC-enriched  ||| S:763 E:776 ||| FW
MCF-7  ||| S:776 E:782 ||| FW
mammospheres  ||| S:782 E:795 ||| FW
( ||| S:795 E:796 ||| -LRB-
MCF-7 MS ||| S:796 E:804 ||| NNP
) ||| S:804 E:805 ||| -RRB-
.  ||| S:805 E:807 ||| .
MCF-7 MS  ||| S:807 E:816 ||| NNP
cells  ||| S:816 E:822 ||| NNS
possessed  ||| S:822 E:832 ||| VBD
typical  ||| S:832 E:840 ||| JJ
BCSC  ||| S:840 E:845 ||| NN
properties ||| S:845 E:855 ||| NNS
,  ||| S:855 E:857 ||| ,
such  ||| S:857 E:862 ||| JJ
as  ||| S:862 E:865 ||| IN
CD44+CD24- ||| S:865 E:875 ||| CD
/ ||| S:875 E:876 ||| CD
low  ||| S:876 E:880 ||| JJ
phenotype ||| S:880 E:889 ||| NN
,  ||| S:889 E:891 ||| ,
high  ||| S:891 E:896 ||| JJ
expression  ||| S:896 E:907 ||| NN
of  ||| S:907 E:910 ||| IN
OCT4  ||| S:910 E:915 ||| NNP
( ||| S:915 E:916 ||| -LRB-
a  ||| S:916 E:918 ||| DT
stem  ||| S:918 E:923 ||| NN
cell  ||| S:923 E:928 ||| NN
marker ||| S:928 E:934 ||| NN
) ||| S:934 E:935 ||| -RRB-
,  ||| S:935 E:937 ||| ,
increased  ||| S:937 E:947 ||| VBD
colony-forming  ||| S:947 E:962 ||| JJ
ability ||| S:962 E:969 ||| NN
,  ||| S:969 E:971 ||| ,
strong  ||| S:971 E:978 ||| JJ
migration  ||| S:978 E:988 ||| NN
and  ||| S:988 E:992 ||| CC
invasion  ||| S:992 E:1001 ||| JJ
capabilities ||| S:1001 E:1013 ||| NNS
,  ||| S:1013 E:1015 ||| ,
differentiation  ||| S:1015 E:1031 ||| JJ
potential ||| S:1031 E:1040 ||| NN
,  ||| S:1040 E:1042 ||| ,
and  ||| S:1042 E:1046 ||| CC
strong  ||| S:1046 E:1053 ||| JJ
tumorigenicity  ||| S:1053 E:1068 ||| NN
in  ||| S:1068 E:1071 ||| IN
xenografted  ||| S:1071 E:1083 ||| JJ
mice ||| S:1083 E:1087 ||| NNS
.  ||| S:1087 E:1089 ||| .
SAL  ||| S:1089 E:1093 ||| NNP
exhibited  ||| S:1093 E:1103 ||| VBD
selective  ||| S:1103 E:1113 ||| JJ
cytotoxicity  ||| S:1113 E:1126 ||| NN
to  ||| S:1126 E:1129 ||| TO
MCF-7 MS  ||| S:1129 E:1138 ||| CD
cells  ||| S:1138 E:1144 ||| NNS
relative  ||| S:1144 E:1153 ||| JJ
to  ||| S:1153 E:1156 ||| TO
MCF-7  ||| S:1156 E:1162 ||| CD
cells ||| S:1162 E:1167 ||| NNS
.  ||| S:1167 E:1169 ||| .
The  ||| S:1169 E:1173 ||| DT
Hh  ||| S:1173 E:1176 ||| JJ
pathway  ||| S:1176 E:1184 ||| NN
was  ||| S:1184 E:1188 ||| VBD
highly  ||| S:1188 E:1195 ||| RB
activated  ||| S:1195 E:1205 ||| VBN
in  ||| S:1205 E:1208 ||| IN
BCSC-enriched  ||| S:1208 E:1222 ||| JJ
MCF-7 MS  ||| S:1222 E:1231 ||| CD
cells  ||| S:1231 E:1237 ||| NNS
and  ||| S:1237 E:1241 ||| CC
SAL  ||| S:1241 E:1245 ||| NNP
inhibited  ||| S:1245 E:1255 ||| FW
Hh  ||| S:1255 E:1258 ||| FW
signaling  ||| S:1258 E:1268 ||| FW
activation  ||| S:1268 E:1279 ||| FW
by  ||| S:1279 E:1282 ||| IN
downregulating  ||| S:1282 E:1297 ||| VBG
the  ||| S:1297 E:1301 ||| DT
expression  ||| S:1301 E:1312 ||| NN
of  ||| S:1312 E:1315 ||| IN
critical  ||| S:1315 E:1324 ||| JJ
components  ||| S:1324 E:1335 ||| NNS
of  ||| S:1335 E:1338 ||| IN
the  ||| S:1338 E:1342 ||| DT
Hh  ||| S:1342 E:1345 ||| NNP
pathway  ||| S:1345 E:1353 ||| VBD
such  ||| S:1353 E:1358 ||| JJ
as  ||| S:1358 E:1361 ||| IN
PTCH ||| S:1361 E:1365 ||| NNP
,  ||| S:1365 E:1367 ||| ,
SMO ||| S:1367 E:1370 ||| NNP
,  ||| S:1370 E:1372 ||| ,
Gli1 ||| S:1372 E:1376 ||| NNP
,  ||| S:1376 E:1378 ||| ,
and  ||| S:1378 E:1382 ||| CC
Gli2 ||| S:1382 E:1386 ||| NNP
,  ||| S:1386 E:1388 ||| ,
and  ||| S:1388 E:1392 ||| CC
subsequently  ||| S:1392 E:1405 ||| RB
repressing  ||| S:1405 E:1416 ||| VBG
the  ||| S:1416 E:1420 ||| DT
expression  ||| S:1420 E:1431 ||| NN
of  ||| S:1431 E:1434 ||| IN
their  ||| S:1434 E:1440 ||| PRP$
essential  ||| S:1440 E:1450 ||| JJ
downstream  ||| S:1450 E:1461 ||| JJ
targets  ||| S:1461 E:1469 ||| NNS
including  ||| S:1469 E:1479 ||| VBG
C-myc ||| S:1479 E:1484 ||| JJ
,  ||| S:1484 E:1486 ||| ,
Bcl-2 ||| S:1486 E:1491 ||| NNP
,  ||| S:1491 E:1493 ||| ,
and  ||| S:1493 E:1497 ||| CC
Snail  ||| S:1497 E:1503 ||| NNP
( ||| S:1503 E:1504 ||| -LRB-
but  ||| S:1504 E:1508 ||| CC
not  ||| S:1508 E:1512 ||| RB
cyclin D1 ||| S:1512 E:1521 ||| CD
) ||| S:1521 E:1522 ||| -RRB-
.  ||| S:1522 E:1524 ||| .
Conversely ||| S:1524 E:1534 ||| RB
,  ||| S:1534 E:1536 ||| ,
Shh-induced  ||| S:1536 E:1548 ||| NNP
Hh  ||| S:1548 E:1551 ||| NNP
signaling  ||| S:1551 E:1561 ||| VBG
activation  ||| S:1561 E:1572 ||| NNS
could  ||| S:1572 E:1578 ||| MD
largely  ||| S:1578 E:1586 ||| RB
reverse  ||| S:1586 E:1594 ||| VB
SAL-mediated  ||| S:1594 E:1607 ||| JJ
inhibitory  ||| S:1607 E:1618 ||| JJ
effects ||| S:1618 E:1625 ||| NNS
.  ||| S:1625 E:1627 ||| .
These  ||| S:1627 E:1633 ||| DT
findings  ||| S:1633 E:1642 ||| NNS
suggest  ||| S:1642 E:1650 ||| VBP
that  ||| S:1650 E:1655 ||| IN
SAL-induced  ||| S:1655 E:1667 ||| JJ
selective  ||| S:1667 E:1677 ||| JJ
cytotoxicity  ||| S:1677 E:1690 ||| NN
against  ||| S:1690 E:1698 ||| IN
MCF-7 MS  ||| S:1698 E:1707 ||| CD
cells  ||| S:1707 E:1713 ||| NNS
is  ||| S:1713 E:1716 ||| VBZ
associated  ||| S:1716 E:1727 ||| VBN
with  ||| S:1727 E:1732 ||| IN
the  ||| S:1732 E:1736 ||| DT
inhibition  ||| S:1736 E:1747 ||| NN
of  ||| S:1747 E:1750 ||| IN
Hh  ||| S:1750 E:1753 ||| NNP
signaling  ||| S:1753 E:1763 ||| VBG
activation  ||| S:1763 E:1774 ||| NNS
and  ||| S:1774 E:1778 ||| CC
the  ||| S:1778 E:1782 ||| DT
expression  ||| S:1782 E:1793 ||| NN
of  ||| S:1793 E:1796 ||| IN
downstream  ||| S:1796 E:1807 ||| JJ
targets  ||| S:1807 E:1815 ||| NNS
and  ||| S:1815 E:1819 ||| CC
the  ||| S:1819 E:1823 ||| DT
Hh  ||| S:1823 E:1826 ||| JJ
pathway  ||| S:1826 E:1834 ||| NN
is  ||| S:1834 E:1837 ||| VBZ
an  ||| S:1837 E:1840 ||| DT
important  ||| S:1840 E:1850 ||| JJ
player  ||| S:1850 E:1857 ||| NN
and  ||| S:1857 E:1861 ||| CC
a  ||| S:1861 E:1863 ||| DT
possible  ||| S:1863 E:1872 ||| JJ
drug  ||| S:1872 E:1877 ||| NN
target  ||| S:1877 E:1884 ||| NN
in  ||| S:1884 E:1887 ||| IN
the  ||| S:1887 E:1891 ||| DT
pathogenesis  ||| S:1891 E:1904 ||| NN
of  ||| S:1904 E:1907 ||| IN
BCSCs ||| S:1907 E:1912 ||| JJ
.  ||| S:1912 E:1914 ||| .
